Pfizer Says Omicron-Specific Vaccine Ready by March
Pfizer also working to improve its current COVID-19 vaccine ‘to address any future variant of potential concern, if needed’
Vaccines
Nearly 600,000 US Children Had COVID-19 Last Week
Since the start of the pandemic, nearly 8.5 million U.S. children have tested positive for COVID-19
Study Supports Coadministration of Prevnar 20 With Pfizer-BioNTech COVID-19 Vaccine
The randomized, double-blind study recruited adults from the phase 3 Pfizer-BioNTech COVID-19 vaccine trial.
Two Doses of BNT162b2 Vaccine Protect Against MIS-C
Two doses of Pfizer-BioNTech vaccine have estimated effectiveness of 91 percent against MIS-C in children aged 12 to 18 years
Vaccination Seems Less Protective Against Transmission of Delta Variant
Reduction in transmission of SARS-CoV-2 associated with COVID-19 vaccination smaller for delta variant versus alpha variant
FDA Shortens Booster Dose Interval for Moderna COVID-19 Vaccine
The Moderna booster dose is authorized for individuals 18 years of age and older.
Moderna CEO Says Fourth COVID-19 Dose May Be Needed Next Fall
Governments, including the United Kingdom and South Korea, are already ordering the doses in preparation, Bancel said
FDA Grants Fast Track Status to Intranasal Pertussis Vaccine
The designation is supported by data from 4 clinical trials evaluating BPZE1 in healthy adults.
CDC Shortens Recommended COVID-19 Isolation, Quarantine Period
The CDC has also updated the recommended quarantine period for individuals exposed to someone with COVID-19.
NVX-CoV2373 Vaccine Protects Against COVID-19
Study conducted in the U.S. and Mexico shows vaccine 90 percent effective overall, 100 percent effective against moderate-to-severe disease
